DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia
|ClinicalTrials.gov Identifier: NCT00899366|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : May 19, 2017
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at tissue samples from patients with T-cell acute lymphoblastic leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: microarray analysis Genetic: mutation analysis Other: immunologic technique|
- Identify the transcriptional signatures associated with the presence of NOTCH1 mutations in primary T-cell acute lymphoblastic leukemia (T-ALL) cells using oligonucleotide microarrays.
- Characterize the global changes on gene expression resulting from the inactivation of NOTCH signaling in human T-ALL lymphoblasts.
OUTLINE: This is a multicenter study.
Frozen lymphoblast samples from patients with T-cell acute lymphoblastic leukemia (NOTCH1-mutated and wild type) are assessed for genetic expression profiles and mutations by microarray analysis and activated NOTCH1 protein by western blot analysis.
PROJECTED ACCRUAL: A total of 48 samples from patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||49 participants|
|Official Title:||Molecular Mechanisms of NOTCH Induced Transformation in T-ALL|
|Actual Study Start Date :||November 30, 2006|
|Actual Primary Completion Date :||March 31, 2013|
|Actual Study Completion Date :||March 31, 2013|
- Transcriptional signatures associated with NOTCH1 mutations in T-cell acute lymphoblastic leukemia (T-ALL) cells [ Time Frame: 1 month ]
- Global changes on gene expression resulting from inactivation of NOTCH signaling in T-ALL cells [ Time Frame: 1 month ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899366
|Study Chair:||Adolfo A. Ferrando, MD, PhD||Herbert Irving Comprehensive Cancer Center|